Related Experiment Video
Updated: Mar 8, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Reduced Lipid Bilayer Thickness Regulates the Aggregation and Cytotoxicity of Amyloid-β
Kyle J Korshavn1,2, Cristina Satriano3, Yuxi Lin4
1From the Department of Chemistry.
Abstract:
The aggregation of amyloid-β (Aβ) on lipid bilayers has been implicated as a mechanism by which Aβ exerts its toxicity in Alzheimer's disease (AD). Lipid bilayer thinning has been observed during both oxidative stress and protein aggregation in AD, but whether these pathological modifications of the bilayer correlate with Aβ misfolding is unclear. Here, we studied peptide-lipid interactions in synthetic bilayers of the short-chain lipid dilauroyl phosphatidylcholine (DLPC) as a simplified model for diseased bilayers to determine their impact on Aβ aggregate, protofibril, and fibril formation. Aβ aggregation and fibril formation in membranes composed of dioleoyl phosphatidylcholine (DOPC) or 1- palmitoyl-2-oleoyl phosphatidylcholine mimicking normal bilayers served as controls. Differences in aggregate formation and stability were monitored by a combination of thioflavin-T fluorescence, circular dichroism, atomic force microscopy, transmission electron microscopy, and NMR. Despite the ability of all three lipid bilayers to catalyze aggregation, DLPC accelerates aggregation at much lower concentrations and prevents the fibrillation of Aβ at low micromolar concentrations. DLPC stabilized globular, membrane-associated oligomers, which could disrupt the bilayer integrity. DLPC bilayers also remodeled preformed amyloid fibrils into a pseudo-unfolded, molten globule state, which resembled on-pathway, protofibrillar aggregates. Whereas the stabilized, membrane-associated oligomers were found to be nontoxic, the remodeled species displayed toxicity similar to that of conventionally prepared aggregates. These results provide mechanistic insights into the roles that pathologically thin bilayers may play in Aβ aggregation on neuronal bilayers, and pathological lipid oxidation may contribute to Aβ misfolding.
Insights
Pathologically thin lipid bilayers, modeled using DLPC, accelerate amyloid-β aggregation and stabilize toxic oligomers in Alzheimer's disease research. These findings offer insights into Aβ misfolding mechanisms in diseased neuronal membranes.
Area of Science:
- Biochemistry
- Neuroscience
- Materials Science
Background:
- Amyloid-β (Aβ) aggregation on lipid bilayers is a key mechanism of toxicity in Alzheimer's disease (AD).
- Lipid bilayer thinning, observed in AD, may influence Aβ misfolding, but the direct correlation remains unclear.
Purpose of the Study:
- To investigate the impact of thinned lipid bilayers, modeled by dilauroyl phosphatidylcholine (DLPC), on amyloid-β (Aβ) aggregation, protofibril, and fibril formation.
- To compare Aβ aggregation in thinned DLPC bilayers versus normal bilayers (DOPC, POPC) and assess the toxicity of resulting aggregates.
Main Methods:
- Utilized synthetic lipid bilayers (DLPC, DOPC, POPC) to model normal and thinned membranes.
- Employed thioflavin-T fluorescence, circular dichroism, atomic force microscopy, transmission electron microscopy, and NMR to monitor Aβ aggregation and fibril formation.
- Assessed the toxicity of Aβ species formed in different lipid environments.
Main Results:
- DLPC bilayers significantly accelerated Aβ aggregation and stabilized non-toxic, globular oligomers at low concentrations, preventing fibrillation.
- DLPC remodeled preformed amyloid fibrils into a pseudo-unfolded, toxic molten globule state.
- Normal bilayers (DOPC, POPC) also catalyzed aggregation but were less efficient than DLPC.
Conclusions:
- Pathologically thin bilayers can significantly alter Aβ aggregation pathways, stabilizing distinct oligomeric species.
- Remodeled Aβ species in thinned bilayers exhibit significant toxicity, implicating lipid oxidation in AD pathogenesis.
- Findings provide mechanistic insights into Aβ-lipid interactions in the context of Alzheimer's disease.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Asymmetric Lipid Bilayer

